To address these gaps, our study aims to comprehensively evaluate the changes in expression levels of TIGIT and its family molecules on NK cells in DLBCL patients and to investigate their functional impact on NK cell-mediated immunity. The gene discussed is TIGIT; the disease is diffuse large B-cell lymphoma.